liptruzet Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Liptruzet, and when can generic versions of Liptruzet launch?
Liptruzet is a drug marketed by Organon and is included in one NDA.
The generic ingredient in LIPTRUZET is atorvastatin calcium; ezetimibe. There are sixty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.
Summary for liptruzet
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for liptruzet |
DailyMed Link: | liptruzet at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for liptruzet
US Patents and Regulatory Information for liptruzet
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-001 | May 3, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-004 | May 3, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-002 | May 3, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-003 | May 3, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for liptruzet
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-003 | May 3, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-002 | May 3, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-001 | May 3, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-004 | May 3, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-001 | May 3, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
Organon | LIPTRUZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 200153-001 | May 3, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for liptruzet
See the table below for patents covering liptruzet around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 3254219 | ⤷ Try a Trial | |
Poland | 324496 | ⤷ Try a Trial | |
Hungary | 221185 | HYDROXY-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTERINEMIC AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND PROCESS FOR PRODUCING THEM | ⤷ Try a Trial |
Norway | 2005003 | ⤷ Try a Trial | |
South Korea | 20030097628 | ⤷ Try a Trial | |
Canada | 2172149 | DERIVES DE SUBSTITUTION HYDROXYLES D'AZETIDINONE, UTILES COMME AGENTS HYPOCHOLESTEROLEMIQUES (HYDROXY-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for liptruzet
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0720599 | SPC/GB03/023 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: DE 54486.00.00 20021017; DE 54488.00.00 20021017; DE 54487.00.00 20021017; DE 54489.00.00 20021017; UK PL 19945/0001 20030404; UK PL 19945/0002 20030404 |
0720599 | 300688 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NATIONAL REGISTRATION NO/DATE: RVG114002-004 20140811; FIRST REGISTRATION: NO 13-9663 - 9665 20140724 |
0720599 | C300688 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NAT. REGISTRATION NO/DATE: RVG114002-004RVG 114008-010 2014110811; FIRST REGISTRATION: 13-9663 - 9665 20140724 |
1003503 | C01003503/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: AMLODIPIN + ATORVASTATIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57633 05.07.2006 |
0720599 | SPC001/2005 | Ireland | ⤷ Try a Trial | SPC001/2005: 20050803, EXPIRES: 20190401 |
0720599 | 26/2005 | Austria | ⤷ Try a Trial | PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON KOMBINIERT MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 1-25673 - 1-25676 20041228; FIRST REGISTRATION: DE 58874.00.00 - 58874.03.00; 58878.00.00 - 20040402 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |